Phase I/II trial of thymosin fraction 5 and thymosin alpha one in HTLV-III seropositive subjects.
R S Schulof(Uniformed Services University of the Health Sciences), Sarah B. Schlesselman, Jane Courtless, David M. Parenti(Milken Institute), Christina Keßler(University Hospital Münster), Phyllis D. Kind, J M Orenstein, Richard A. DiGioia(George Washington University), Gy. Simon, Marcelo B. Sztein(University of Maryland, Baltimore)
PubMed
October 1, 1986
Cited by 11
Related Papers
Serum Levels of the Proinflammatory Cytokines Interleukin-1 Beta (IL-1β), IL-6, IL-8, IL-10, Tumor Necrosis Factor Alpha, and IL-12(p70) in Malian Children with Severe<i>Plasmodium falciparum</i>Malaria and Matched Uncomplicated Malaria or Healthy Controls
|Infection and Immunity|2004|447
Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road
|Nature Reviews Microbiology|2007|372
Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans
|Infection and Immunity|1997|251
Immunology of gut mucosal vaccines
|Immunological Reviews|2010|247
Vaccination in the elderly: an immunological perspective
|Trends in Immunology|2009|237